Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: Results of a retrospective analysis of the PROTECHT study

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Barni, Sandro ^a   Labianca, Roberto ^b   Agnelli, Giancarlo ^c   Bonizzoni, Erminio ^d   Verso, Melina ^c   Mandalà, Mario ^b   Brighenti, Matteo ^e   Petrelli, Fausto ^a   Bianchini, Carlo ^f   Perrone, Tania ^f   Gasparini, Giampietro ^g  

^a TREVIGLIO HOSPITAL   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e CREMONA HOSPITAL   (Italy)

^f Italfarmaco SpA   (Italy)

^g SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Chemotherapy; LMWH; Nadroparin; Prophylaxis; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; STEROID; TRASTUZUMAB; VINCA ALKALOID; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; OVARY CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STOMACH CANCER; THROMBOEMBOLISM; AGED; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; NEOPLASM; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NADROPARIN; NEOPLASMS; OUTPATIENTS; RISK FACTORS; THROMBOEMBOLISM;

EID: 80054686355     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-179     Document Type: Article

References (35)

1. Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66329 cancer patients: results of a record linkage study. J Thromb Haemost 2006, 4:529-35. 10.1111/j.1538-7836.2006.01804.x, 16460435.
2. White RH, Chew HK, Zhou H, Parikh-Patel A, Harris D, Harvey D, Wun T. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005, 165:1782-7. 10.1001/archinte.165.15.1782, 16087828.
3. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH, Somerfield MR, Einhaus K, Hagerty KL, Brouwers MC. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007, 5:632-4. 10.1111/j.1538-7836.2007.02374.x, 17319909.
4. Schwartz JD, Simantov R. Thrombosis and malignancy: pathogenesis and prevention. In Vivo 1998, 12:619-24.
5. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006, 118:555-68. 10.1016/j.thromres.2005.10.015, 16388837.
6. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998, 338:1169-73. 10.1056/NEJM199804233381701, 9554856.
7. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999, 78:285-91.
8. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in prospective observational study. Cancer 2005, 104:2822-29. 10.1002/cncr.21496, 16284987.
9. Nadir Y, Hoffman R, Brenner B. Drug-related thrombosis in hematologic malignancies. Rev Clin Exp Hematol 2004, 8:E4.
10. Blom JW, Doggen CJ, Osanto S, Osendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005, 293(6):715.. 10.1001/jama.293.6.715, 15701913.
11. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000, 160(6):809. 10.1001/archinte.160.6.809, 10737280.
12. Kröger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, Urbanski K, Seeber S, Scheulen ME. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006, 17:297-303.
13. Starling N, Rao S, Cunningham D, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: A report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009, 27:3786-3793. 10.1200/JCO.2008.19.4274, 19398575.
14. Dasanu CA. Gemcitabine: Vascular toxicity and prothrombotic potential. Expert Opin Drug Saf 2008, 7(6):703-16. 10.1517/14740330802374262, 18983217.
15. Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol 1986, 4:1405-1417.
16. Tham J, Albertsson M. Upper extremity deep venous thrombosis in patients with 5-fluorouracilcontaining adjuvant chemotherapy--three case reports and a review. Acta Oncol 2004, 43:108-112. 10.1080/02841860310021545, 15068328.
17. Blom JW, Osanto S, Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur J Cancer 2006, 42:410-414. 10.1016/j.ejca.2005.09.013, 16321518.
18. Yoshikawa R, Yanagi H, Noda M, Ikeuchi H, Nakano H, Gega M, Tsukamoto K, Oshima T, Inoue T, Fujiwara Y, Shoji Y, Sakaki T, Higasa S, Hashimoto-Tamaoki T, Yamamura T. Venous thromboembolism in colorectal cancer patients with central venous catheters for 5-FU infusion-based pharmacokinetic modulating chemotherapy. Oncol Rep 2005, 13:627-632.
19. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M, . PROTECHT Investigators Nadroparin for the prevention of thromboembolic events in outpatients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009, 10(10):943-9. 10.1016/S1470-2045(09)70232-3, 19726226, PROTECHT Investigators.
20. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, . American College of Chest Physicians Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2008, 133:381S-453S. 8, 10.1378/chest.08-0656, 18574271, American College of Chest Physicians.
21. Noble S. A step in the right direction, but one size might not fi t all. Lancet Oncol 2009, 10(10):930-1. 10.1016/S1470-2045(09)70293-1, 19796745.
22. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008, 111(10):4902-4907. 10.1182/blood-2007-10-116327, 2384124, 18216292.
23. Cohen AT, Nandini B, Wills JO, Ota S. VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients. Thromb Res 2010, 125(Suppl 2):S21-9.
24. Agnelli G, Verso M. Thromboprophylaxis during chemotherapy in patients with advanced cancer. Thromb Res 2010, 125(Suppl 2):S17-20.
25. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009, 27(29):4865-73. 10.1200/JCO.2009.22.3875, 19704059.
26. Kuenen BC, Levi M, Meijers JC, van Hinsbergh VW, Berkhof J, Kakkar AK, Hoekman K, Pinedo HM. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 2003, 21:2192-8. 10.1200/JCO.2003.08.046, 12775746.
27. Zecchina G, Ghio P, Bosio S, Cravino M, Camaschella C, Scagliotti GV. Reactive thrombocytosis might contribute to chemotherapy-related thrombophilia in patients with lung cancer. Clin Lung Cancer 2007, 8:264-7. 10.3816/CLC.2007.n.004, 17311691.
28. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG. Phase II trial of gemcitabine (2,2'-difl uorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994, 12:29-34. 10.1007/BF00873232, 7960602.
29. Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, Bourgeois E, Thieblemont C, Leleu X, Hequet O, Salles G, Coiffier B. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 2001, 113:772-8. 10.1046/j.1365-2141.2001.02795.x, 11380469.
30. Numico G, Garrone O, Dongiovanni V, Silvestris N, Colantonio I, Di Costanzo G, Granetto C, Occelli M, Fea E, Heouaine A, Gasco M, Merlano M. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005, 103:994-9. 10.1002/cncr.20893, 15666321.
31. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E, , . Arbeitsgemeinschaft Internistische Onkologie Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008, 26(9):1435-42. 10.1200/JCO.2007.13.9378, 18349393, Arbeitsgemeinschaft Internistische Onkologie Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin.
32. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, Soff G, Parameswaran R, Hassoun H. High incidence of thromboembolic events in patients treated with Cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011, 29(25):3466-73. 10.1200/JCO.2011.35.5669, 21810688.
33. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O''Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010, 28(22):3617-22. 10.1200/JCO.2010.28.1386, 2917317, 20606091.
34. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine - reporting of subgroup analyses in clinical trials. N Engl J Med 2007, 357:2189-94. 10.1056/NEJMsr077003, 18032770.
35. Cook DI, Gebski VJ, Keech AC. Subgroup analysis in clinical trials. MJA 2004, 180(6):289-291.